Open for inclusion

A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab) in Advanced Solid Tumors

Cancer type: HCC, Lung cancer, Melanoma

Phase: I/II

Principal Investigator: Nyakas Martha

Country: NO

Keywords: Norway, Oslo, Lung, Melanoma, HCC

Status: Open for inclusion

Link to